PDS Biotechnology Corp 10-Q

ITEM 5. OTHER INFORMATION None . 32 ITEM 6. EXHIBITS EXHIBIT INDEX Exhibit Number Exhibit Description 4.1 Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025). 4.2 Form of Common Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025). 4.3 Form of Debenture (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 4.4 Form of Warrant (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 10.1 Form of Securities Purchase Agreement dated February 26, 2025, by and between PDS Biotechnology Corporation and the Purchasers (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025). 10.2 Placement Agency Agreement dated February 26, 2025, between PDS Biotechnology Corporation and A.G.P./Alliance Global Partners (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on February 28, 2025). 10.3 + Securities Purchase Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation, the purchasers named therein, and JGB Collateral LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 10.4 Registration Rights Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation and the purchasers named therein (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 10.5 Security Agreement, dated April 30, 2025, by and among PDS Biotechnology Corporation., each of PDS Biotechnology Corporation’s specified subsidiaries named therein, the purchasers named therein and JGB Collateral LLC (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 10.6 Form of Subsidiary Guarantee (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K, filed with the SEC on May 2, 2025). 31.1 * Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 * Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 * Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). 32.2 * Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith). 101.INS* Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH* Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. 101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF* XBRL Taxonomy Extension Definition Linkbase Document 101.LAB* XBRL Taxonomy Extension Label Linkbase Document 101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Filed herewith (unless otherwise noted as being furnished herewith) + Pursuant to Item 601(a)(5) of Regulation S-K, schedules have been omitted and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request. 33 SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PDS Biotechnology Corporation May 14, 2025 By: /s/ Frank Bedu-Addo Frank Bedu-Addo, Ph.D. President and Chief Executive Officer (Principal Executive Officer) May 14, 2025 By: /s/ Lars Boesgaard Lars Boesgaard Chief Financial Officer (Principal Financial and Accounting Officer) 34